Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
{{output}}
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been widely used as first-line (1L) treatment of advanced ALK+ non-small cell lung cancer (NSCLC) ever since its approved indication on November 17, 2017... ...
